Encision Q4 2025 Earnings Report

Encision EPS Results

• Actual EPS: -$0.01
• Consensus EPS: N/A
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Encision Revenue Results

• Actual Revenue: $1.58 million
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Encision Announcement Details

• Quarter: Q4 2025
• Date: 7/10/2025
• Time: After Market Closes
• Conference Call Date: N/A
• Conference Call Time: N/A

Encision (OTCMKTS:ECIA), Inc. is a U.S.-based medical device company specializing in the development and commercialization of safety solutions for electrosurgery. Founded in the early 1990s, the company’s core mission is to reduce the risk of unintended thermal injuries during surgical procedures by controlling stray electrical current. Encision’s operations focus on research, design, and manufacturing of proprietary instruments and monitoring systems that integrate seamlessly with existing surgical equipment.

At the heart of Encision’s product offering is its Active Electrode Monitoring (AEM) platform. The AEM system continuously detects and senses stray currents that may otherwise escape from standard electrosurgical instruments. By automatically interrupting the electrical output when unsafe current paths are detected, AEM enhances patient safety without compromising surgical performance. Encision complements this technology with a range of insulated laparoscopic and open surgery instruments, cables, and accessories designed to work exclusively within the AEM ecosystem.

Encision markets its AEM-enabled instruments and supporting products directly to hospitals, ambulatory surgery centers, and distributor networks across the United States, Europe and select international territories. The company builds strategic partnerships with surgical device distributors and leverages a direct sales force to provide training, technical support and clinical education for surgeons and operating room personnel. This global footprint underscores Encision’s commitment to expanding awareness of electrosurgical safety and improving patient outcomes worldwide.

Intellectual property protection is a cornerstone of Encision’s business strategy. The company maintains a portfolio of patents covering its monitoring algorithms, instrument insulation techniques and connector designs. Encision’s headquarters and manufacturing facilities operate under stringent quality management systems compliant with U.S. Food and Drug Administration (FDA) regulations and international medical device standards. This regulatory focus and patent-backed innovation underscore the company’s role as a specialized provider of electrosurgical safety technology.